Welcome to the Emerging Pathogens & Infectious Diseases Consortium
Welcome to EPIC – the Emerging Pathogens and Infectious Diseases Consortium.
EPIC brings together researchers, clinicians, and institutions across the University of Toronto and its hospital partners to advance infectious disease research and build lasting resilience against emerging threats.
This work builds on a long legacy: EPIC partners have played an integral role in infectious disease research for a century, from work that helped control diphtheria and eradicate smallpox, to today’s front-line research in antimicrobial resistance and infection control. Our collective response to COVID-19, highly pathogenic avian influenza, and mpox makes clear there’s never been a more important time to advance that work, from emerging pathogens and antimicrobial resistance to health inequities and public trust.
Building on this momentum, EPIC marshals the advanced research infrastructure and world-renowned research and training expertise of our EPIC partners to deliver an integrated, innovative response to the infectious disease challenges facing communities today and in the future.
Seven EPIC research clusters
Antimicrobial Resistance
Protecting the effectiveness of the medicines we depend on.
Chronic Infections
Addressing the long-term burden of infections that don’t resolve.
Emerging Pathogens
Detecting and responding to new and re-emerging threats before they spread.
Health Inequities
Ensuring infectious disease research and response reach everyone, equitably.
Health Systems Resilience
Building health systems that bend, not break, under infectious threats.
Misinformation, Disinformation & Public Trust
Strengthening public trust through clear, credible information.
Sepsis & Acute Respiratory Distress
Improving detection and treatment when every minute counts.
EPIC News
A new bivalent vaccine offers hope for preventing antibiotic-resistant Neisseria gonorrhoeae infections
(left to right) Jamie Fegan and Epshita Islam with Trevor Moraes By Sunitha Chari Researchers at the University of Toronto have developed a new vaccine formulation for the sexually transmitted infection (STI) gonorrhea. The formulation comprises two antigens derived...
IfP Graduate Studentship Award recipient explores new methods for investigating long COVID
March 24, 2025 By Chloe Panganiban This story was originally published on the Institute of Health Emergencies and Pandemics (IHEP) website. Priyonto Saha’s passion for interdisciplinary learning and research stems from an academic background through the data and...
EPIC recognizes the outstanding scientific contributions of four young researchers through the 2025 Future Leaders Prizes
(left to right) Patrick Budylowski, Ashley Campbell, Julien Couture-Senecal, James Zhu March 14, 2025 By Sunitha Chari Today the University of Toronto’s Emerging & Pandemic Infections Consortium (EPIC) announced the winners of the 2025 Future Leaders Prizes. The...
